Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular ...
May 25, 2023
0
2
New animal research is helping explain why at least five people have become HIV-free after receiving a stem cell transplant. The study's insights may bring scientists closer to developing what they hope will become a widespread ...
May 25, 2023
1
29
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in ...
Apr 26, 2023
0
2
Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs' effects within a year.
Apr 24, 2023
0
34
Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. ...
Apr 17, 2023
0
2
Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ...
Apr 4, 2023
0
7
A team of Harvard and Sloan Kettering scientists has developed compounds that can target and degrade proteins associated with acute myeloid leukemia (AML) and nearly doubled the life expectancy of mice with cancer in laboratory ...
Apr 3, 2023
0
74
In a world first, Newcastle researchers have discovered the mechanisms acute myeloid leukemia (AML) cells use to produce "free radicals"—the byproduct of a cell process that aggressively fuels the growth of cancer cells ...
Mar 29, 2023
0
46
With the combination of the drugs Venetoclax and 5-Azacitidine, a new, effective and more tolerable alternative to chemotherapy for the treatment of AML has been available for several years. But for some patients, the drug ...
Mar 16, 2023
0
1
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements ...
Mar 15, 2023
0
27
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of the disease remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
AML has several subtypes; treatment and prognosis varies among subtypes. 5-year survival varies from 15-70%, and relapse rate varies from 78-33%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has developed tests that better predict how long a patient is likely to survive and whether a drug is likely to be effective.
This text uses material from Wikipedia, licensed under CC BY-SA
